MedTrace Logo

Pharmacogenomics of Drug Safety in Multiple Sclerosis

NCT01118130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-01-14

No results posted yet for this study

Summary

To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after exposure to beta-interferon for MS.

Conditions

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Canada Foundation for Innovation

    collaborator OTHER

  • Genome Canada

    collaborator OTHER

  • British Columbia Clinical Genomics Network

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Bruce Carleton · University of British Columbia

  • Michael Hayden · University of British Columbia

  • Helen Tremlett · University of British Columbia

  • Anthony Traboulsee · University of British Columbia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118130 on ClinicalTrials.gov